Talha Badar, Hematology/Oncology Specialist at Mayo Clinic shared a post on X:
“Can BRAF inhibition move earlier in the treatment course for hairy cell leukemia?
In our multicenter real-world cohort of 110 patients, frontline vemurafenib-based regimens achieved an ORR of 80%, with durable remissions observed in selected patients, despite being used in older and more cytopenic populations.
Important step toward chemotherapy-sparing strategies for HCL.”
Title: Real-world treatment and outcomes in hairy cell leukemia: a multicenter retrospective cohort including BRAF inhibitor therapy
Authors: James J. Fradin, Lisa Rein, Aniko Szabo, Karen-Sue Carlson, Talha Badar, Troy Holden, Shiv Shah, Annie Im, Anand A. Patel, Ehab Atallah
Read the article here.
Other articles about Hairy Cell Leukemia on OncoDaily.
